Thioacetazone
Top View
- WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment
- Host-Directed Therapeutics As a Novel Approach for Tuberculosis Treatment Ye-Ram Kim1,2 and Chul-Su Yang1,2*
- Computational Annotations of Mycobacterial Rv3632 That Confers Its Efficient Function in Cell Wall Biogenesis
- WHO/CDS/TB/2003.313 Treatment of Tuberculosis: Guidelines for National Programmes, Third Edition Revision Approved by STAG, June 2004
- WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update
- The Selection and Use of Essential Medicines
- The Decrease in Antibiotic Funding
- Public Assessment Report
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Marrakesh Agreement Establishing the World Trade Organization
- WHO Consolidated Guidelines on Tuberculosis WHO Operational
- Tetroxoprim/Thioacetazone 351 Thenoic Acid Cross-Resistance Occurs Between Thiamphenicol and Chloram- Reactions Associated with Thioacetazone
- Preventing and Minimizing Risks Associated with Antituberculosis Medicines to Improve Patient Safety
- Medicines Amendment Regulations (No 2) 2015
- Group 5 Drugs for Multidrug-Resistant Tuberculosis: Individual Patient Data Meta-Analysis
- Pharmaabkommen A1 E
- Global Drug Facility
- A Dissertation Entitled Structural and Enzymatic Studies of Essential